"Penicillin, one of the scientific marvels of the 20th century, is currently losing a lot of battles it once won against bacterial infections," researchers said.
Now, scientists at the University of South Carolina have reported a new approach to restoring its combat effectiveness, even against so-called superbugs.
Bacteria have been chipping away at the power of the penicillin family of drugs since their first wide-scale use as antibiotics in the 1940s, researchers said.
A cyclic four-membered amide ring termed a beta-lactam is a common structural element of the penicillins, their synthetic and semi-synthetic derivatives.
One of the most effective bacterial defences is an enzyme called beta-lactamase, which chews up the beta-lactam structure, researchers said.
Some bacteria, such as MRSA, have developed the ability to biosynthesise and release beta-lactamase when needed.
The new approach by Carolina's Chuanbing Tang pairs the drug with a protective polymer developed in his chemistry laboratory.
In lab tests, graduate student Jiuyang Zhang prepared a cobaltocenium metallopolymer that greatly slowed the destructiveness of beta-lactamase on a model beta-lactam molecule (nitrocefin).
The enhancement was modest against two strains, but very pronounced with the hospital-associated strain of MRSA (HA-MRSA).
The metallopolymer by itself even demonstrated antimicrobial properties, lysing bacterial cells while leaving human red blood cells unaffected.
By a variety of measures, the polymer was found to be nontoxic to human cells in laboratory tests.
The research was published in the Journal of the American Chemical Society.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
